Metabolic Elite and Hofseth BioCare (HBC) will work together to develop a “premium range of performance nutrition products for elite athletes.”
The products will be available for pre-order at A4M, the Longevity Fest event taking place from Dec. 12 to 14 in Las Vegas, a spokesperson for HBC told NutraIngredients. The initial launch will target the United States, but the brands are expected to be available in Canada soon.
“I’m excited to collaborate with HBC to create a breakthrough medical nutrition brand,” said Jim LaValle, chief science officer of Lifetime and founder of Metabolic Code, a cloud-based performance health end to end solution. “Together, we’ll create solutions that empower individuals to unlock their full metabolic potential while maintaining long-term vitality.”
LaValle is also co-chair for the American Academy of Anti-Aging Medicine (A4M) and chair of the International Peptide Society.
The ingredient trifecta
James Berger, CCO at Hofseth BioCare ASA, confirmed to NutraIngredients that the partnership will apply to all three of HBC’s ingredients: ProGo, a mix of bioactive peptides and collagen; OmeGo, a whole salmon oil with all the fatty acid fractions contained in fish; and CalGo / NT-II salmon bone powder containing calcium hydroxyapatite and undenatured collagen for bone and joint health. All three ingredients are upcycled from Atlantic salmon (Salmo salar).
ProGo is reported to improve iron metabolism by boosting the body’s ability to take up and use iron resulting in increased energy and vitality. Data published last year in Marine Drugs also found that a fraction of the peptides, the smallest peptides in ProGo, are activating the GLP-1 receptor. The peptides also show pancreatic protection—insulin is produced in the pancreas.
CalGo / NT-II has shown both bone and joint health benefits to support healthy aging and active lifestyles, the company shared.
OmeGo is positioned for heart, cognitive, eye and joint health, with data from HBC studies showing that the oil may reduce serum levels of oxLDL-GP, an independent biomarker of cardiovascular risk, which the company linked to its anti-oxidation effects, and not from the EPA and DHA fractions.
Recent research around immune support and respiratory health is creating new opportunities for the ingredient.
